Old Web
English
Sign In
Acemap
>
authorDetail
>
Jacob Wesley
Jacob Wesley
MedImmune
Medicine
Mucopolysaccharidosis type I
Disease
Enzyme replacement therapy
Heparan sulfate
5
Papers
81
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.
2021
Christiane S. Hampe
Jacob Wesley
Troy C. Lund
Paul J. Orchard
Lynda E. Polgreen
Julie Eisengart
Linda K. McLoon
Sebahattin Cureoglu
Patricia A. Schachern
R. Scott McIvor
Show All
Source
Cite
Save
Citations (6)
Differences in MPS I and MPS II Disease Manifestations.
2021
International Journal of Molecular Sciences
Christiane S. Hampe
Brianna Yund
Paul J. Orchard
Troy C. Lund
Jacob Wesley
R. Scott McIvor
Show All
Source
Cite
Save
Citations (1)
Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.
2020
Cells
Christiane S. Hampe
Julie Eisengart
Troy C. Lund
Paul J. Orchard
Monika Swietlicka
Jacob Wesley
R. Scott McIvor
Show All
Source
Cite
Save
Citations (5)
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study:
2019
Multiple Sclerosis Journal
Mark Agius
Gabriela Kłodowska-Duda
Maciej Maciejowski
Andrzej Potemkowski
Jing Li
Kaushik Patra
Jacob Wesley
Soraya Madani
Gerard Barron
Eliezer Katz
Armando Flor
Show All
Source
Cite
Save
Citations (69)
The American Pharm.D. Parkour
2017
Journal of Pharmaceutical Science and Technology, Japan
Jacob Wesley
Andongfac Nkobena
Show All
Source
Cite
Save
Citations (0)
1